• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Pharma Supply Chains: From Fragile to Agile

    Advanced Manufacturing and a Roadmap to the Facility of the Future

    Solving Pharma’s Underlying Rebate Leakage Problem

    Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges

    Revolutionizing Pharma’s Supply Chain
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Univercells Expands into the U.S. With New Offices in Andover, MA

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Ionis, Roche Partner on RNA-targeted Programs for AD and HD

    Sanner Group Opens Second Manufacturing Facility in China

    Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Univercells Expands into the U.S. With New Offices in Andover, MA

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Sanner Group Opens Second Manufacturing Facility in China

    Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems

    "3 Key Trends" with Srinivasan Shanmugam
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Pharmaceutical Continuous Manufacturing: USP Technical Guide

    Mikart Expands Production and Packaging Capabilities

    Flavor Masking for Rx and OTC Drugs

    Prefilled Syringe Production: Filling a Need with Modern Equipment

    Making the Complex, Simple: A Roadmap for Your OSD Journey
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment

    Ionis, Roche Partner on RNA-targeted Programs for AD and HD

    Modern Partnerships with CROs

    Merck KGaA, Quris-AI Expand Collaboration

    BioCity, AstraZeneca Partner on Treatment of Advanced HCC
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges

    Rentschler Biopharma’s ATMP UK Facility Receives MHRA Approval

    Aurisco's Manufacturing Site in China Clears FDA Inspection

    LighthouseAI Secures $2.25M Investment to Grow Supply Chain Products

    Valisure, DoD Conduct Pharmaceutical Quality Risk Assessment Study
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    CMC Pharmaceuticals

    Syngene International Ltd.

    Societal CDMO

    Quotient Sciences

    LOTTE BIOLOGICS
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    CMC Pharmaceuticals

    Syngene International Ltd.

    Societal CDMO

    Quotient Sciences

    LOTTE BIOLOGICS
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Top Companies Report

    Bayer

    ...

    Bayer
    07.15.19
    Headquarters: Leverkusen, Germany
    twitter.com/Bayer
    www.bayerpharma.com



    Headcount:  116,998
    Year Established: 1971
    Revenues:  $45,278   (+13%)
    Pharma Revenues:  $19,154   (-1%)
    Net Income:  $1,934  (-77%)
    R&D:  $6,000   (+16%)

    TOP SELLING DRUGS   
    Drug Indication 2018 Sales (+/-%)
    Xarelto atrial fibrillation $3,689 17%
    Eylea macular degeneration $2,581 21%
    Mirena women’s health $1,350 6%
    Kogenate hemophilia $1,010 -8%
    Nexavar oncolgy $841 -11%
    Yasmin contraception $755 3%
    Precose diabetes $733 16%
    Adalat hypertension $722 -1%
    Asprin Cardio Myocardial infarction prophylaxis $658 0%
    Betaferon multiple sclerosis $643 -13%


    After Bayer made the mega $63 billion deal for Monsanto, turning it into the world’s largest agro-chemical maker and seed producer, it was forced to make some major overhauls.

    The company announced at the end of the year it would be axing 12,000 jobs throughout the crop science, pharma and consumer units. Of the job losses, roughly 1,250 were in pharma with 350 related directly to a new manufacturing facility in Wuppertal, Germany that the company will not use, focusing all recombinant factor VIII production at its Berkeley, CA site instead.

    In addition, as this issue went to press Bayer had already sold off the iconic Coppertone skin care brand and was still looking for a buyer for the Dr. Scholl’s foot care brand and its animal health unit. China’s Fosun International, parent of Fosun Pharma, was on the hunt for the animal health business, looking to partner with private equity to make an offer—the sale could be worth nearly $8 billion if it goes down.

    With all the shake-ups, pharma sales were off by just one percent for the year ($19.2 bn) when factoring in exchange rates. Growth in pharma is being driven primarily driven by its top selling drug Xarelto and Eylea, with several promising late-stage R&D pipeline candidates. Sales of the oral anticoagulant Xarelto were up 17% and eye medicine Eylea climbed 21% while cancer drugs Stivarga and Xofigo, and the pulmonary hypertension treatment Adempas advanced by 13.5%.

    Looking ahead to the eventual loss of exclusivity for Xarelto and Eylea, Bayer is amping up its oncology pipeline. At the end of 2017 it made a deal with Loxo Oncology to develop and commercialize larotrectinib and LOXO-195, Loxo Oncology’s franchise of highly selective TRK inhibitors for patients with TRK fusion cancers. A year later, in November 2018, FDA approved larotrectinib, which is now sold under the brand name Vitrakvi.

    More good news came on the cancer treatment front when Bayer reported positive results of the Phase III study of darolutamide, a novel androgen receptor antagonist of for the oral treatment of prostate cancer that is being developed jointly by Bayer and the Finnish biopharmaceutical company Orion Corporation.

    Research and development of new immunotherapy approaches in oncology continued through a partnership with Compugen Ltd., a company focused on predictive discovery and development of therapeutics for cancer immunotherapy. COM902, its lead anti-TIGIT antibody, advanced into manufacturing for an investigational new drug (IND) application that was anticipated in 2019. The companies entered into a process development and manufacturing service agreement to produce COM902 for future use in clinical trials.

    With the University of Texas MD Anderson Cancer Center it signed a five-year collaboration agreement to accelerate the development of novel targeted treatments based on patient or tumor characteristics for which current therapies have not shown satisfactory clinical efficacy. Bayer will contribute early stage as well as clinical assets from its development pipeline for further clinical development at MD Anderson Cancer Center. The MD Anderson Cancer Center will bring in its translational and clinical expertise to help accelerate ongoing and future clinical trials.

    Beyond cancer
    Bayer entered a few collaborations during the year outside the cancer realm. With the Broad Institute of MIT and Harvard, Bayer launched the joint Precision Cardiology Laboratory, which will pursue novel scientific insights to enable the development of new therapies for patients with cardiovascular diseases such as heart failure. Heart failure—a general diagnosis given when the heart doesn’t pump effectively—is a composite of multiple factors, and as such requires new tools and methods to gain deeper knowledge to benefit patients. The scientists at the joint laboratory will combine Broad Institute’s methods for basic science discovery such as single cell sequencing and clinical expertise with Bayer’s long experience in drug development to discover new potential therapeutics.

    Furthermore, Bayer and Haplogen GmbH, a Vienna-based biotechnology company, entered into a multi-year research collaboration agreement to identify new drug candidates for the treatment of pulmonary diseases such as chronic obstructive pulmonary disease (COPD). COPD is a common and heterogeneous respiratory disease that causes breathlessness and predisposes to exacerbations and serious illness. Respiratory viral infections are one frequent cause of COPD exacerbations. One possible treatment approach for COPD exacerbations is to disrupt the multiplication of the responsible virus by inhibiting its replication. The goal of the research alliance is to develop new antiviral compounds addressing the high unmet medical need in reducing COPD exacerbations.

    At the start of 2019, Bayer and Kyoto University agreed on a strategic research alliance to jointly identify new drug targets for the treatment of pulmonary diseases such as idiopathic pulmonary fibrosis. The goal of the research alliance is to identify specific targets and pathways that are causing the disease and to discover new treatments to modulate these pathways and prevent further lung functions decline. Bayer has an option for the exclusive use of the collaboration results. 
    Related Searches
    • immunotherapy
    • Development
    • china
    • Phase III
    Suggested For You
    Legacy Pharma Solutions Legacy Pharma Solutions
    PCI Pharma Services PCI Pharma Services
    Catalent Pharma Solutions Catalent Pharma Solutions
    Mogene Mogene
    Regis Custom Pharma Regis Custom Pharma
    Softweb Solutions Softweb Solutions
    Fermion Oy, a subsidiary of Orion Corporation Fermion Oy, a subsidiary of Orion Corporation
    Adare Pharma Solutions Adare Pharma Solutions
    FDA Accepts RedHill Biopharma’s NDA for Talicia FDA Accepts RedHill Biopharma’s NDA for Talicia
    Pistoia Alliance, backed by Roche, AZ and Bayer, to Introduce FAIR Project Pistoia Alliance, backed by Roche, AZ and Bayer, to Introduce FAIR Project
    Top 25 Pharma and Biopharma Companies Top 25 Pharma and Biopharma Companies
    Lilly Lilly
    Syndax Pharma Gets IND Clearance for Leukemia Treatment Syndax Pharma Gets IND Clearance for Leukemia Treatment
    The FDA Gets Stricter with E&L Oversight, Can the Industry Keep Up? The FDA Gets Stricter with E&L Oversight, Can the Industry Keep Up?
    Loxo Oncology Enters Strategic Pact with AmoyDx, PREMIA Loxo Oncology Enters Strategic Pact with AmoyDx, PREMIA

    Related Buyers Guide Companies

    • Legacy Pharma Solutions

      Legacy Pharma Solutions

      ...
      Nathan Bender, Director, Sales & Marketing 12.07.21

    • Drug Development
      PCI Pharma Services

      PCI Pharma Services

      ...
      Tania Moorehead, Global Marketing Manager 10.20.21

    • Drug Delivery
      Catalent Pharma Solutions

      Catalent Pharma Solutions

      ...
      Christopher, Director, Global Communications and Marketing 11.25.20


    • Mogene

      ...
      Craig Morley, CEO 11.17.20

    • APIs | Clinical Trial Materials | Process Validation | QA/QC | Regulatory Affairs

      Regis Custom Pharma

      ...
      Deanna Rentner, Marketing Coordinator 11.12.20

    Loading, Please Wait..
    Breaking News
    • Univercells Expands into the U.S. With New Offices in Andover, MA
    • Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment
    • Ionis, Roche Partner on RNA-targeted Programs for AD and HD
    • Sanner Group Opens Second Manufacturing Facility in China
    • Körber Integrates Werum PAS-X MES with Bausch+Ströbel Systems
    View Breaking News >
    CURRENT ISSUE

    September 2023

    • Pharma Supply Chains: From Fragile to Agile
    • Overcoming Stressors in Knowledge Transfer
    • Innovations in Pharma Packaging
    • HPAPI Manufacturing Trends
    • Sustainable Packaging in Pharma: No Longer a Pipe Dream
    • Revolutionizing Pharma’s Supply Chain
    • Pharmaceutical Labeling: Overcoming Regulatory & Operational Challenges
    • Solving Pharma’s Underlying Rebate Leakage Problem
    • Advanced Manufacturing and a Roadmap to the Facility of the Future
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    D2C Supplement Brand Launches Blood Sugar Support Supplement, Gluco-Control
    Natrol Launches First Non-Melatonin Sleep Supplement
    Metagenics Releases Consumer Survey on Menopausal Support Supplement
    Coatings World

    Latest Breaking News From Coatings World

    Coating Additives Market Worth $10.5B by 2028: MarketsandMarkets
    California Sports Surfaces Celebrates 70 Years
    ROSS Offers Cost-Effective, Expertly Reconditioned Equipment
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    MPO's Most-Read Stories This Week—Sept. 30
    Dentsply Sirona Names Former NuVasive CEO Lucier as Chairman
    SeaStar Medical Gets Breakthrough Nod for Selective Cytopheretic Device
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Univercells Expands into the U.S. With New Offices in Andover, MA
    Evecxia Therapeutics, Quotient Sciences Complete Clinical Milestone for Depression Treatment
    Ionis, Roche Partner on RNA-targeted Programs for AD and HD
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    MAV Beauty Recruits Former Elizabeth Arden CEO Scott Beattie
    YSL Beauty Taps Finn Wolfhard, Lil Yachty & More for Fragrance Campaign
    74% of Makeup Users Open to Affordable ‘Dupes,’ Mintel Says
    Happi

    Latest Breaking News From Happi

    Is Dr. Barbara Sturm Skincare Considering a Sale?
    YSL Beauty Welcomes Five Foremost Artists to Represent New Fragrance
    Christian Siriano Appointed Olay’s First Chief Drop Officer
    Ink World

    Latest Breaking News From Ink World

    MicroDynamics, All Printing Resources Partner to Represent Veritas
    Weekly Recap: Wikoff Color, BASF, Latin America Top This Week’s Stories
    Siegwerk’s Climate Targets Validated by SBTi
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    SABIC and partners launch bio-based IML solution for food packaging
    tesa completes expansion of Michigan manufacturing facility
    Comexi and Asahi to host 'Effortless Platemaking' event
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Greentech Introduces Air Filter with Advanced Odor Elimination
    Ontex Divests Pakistan Operations to ASAIA Holding
    Goodnites Bedwetting Underwear Recognized by Good Housekeeping
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    ODT's Most-Read Stories This Week—Sept. 30
    Lazurite Adds Benchmark Medical as a Distributor for its ArthroFree Wireless Camera System
    ChitogenX Granted New U.S., Canadian ORTHO-R Patent
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: Mergers and Acquisitions, First Solar Top This Week’s Stories
    Jabil Posts Fourth Quarter, Fiscal Year 2023 Results
    Ink-Borne ‘Chiplets’ Could Lead to Printable Displays, Electronics and More

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login